Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis
Phase 2
Recruiting
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Other: Autologous peripheral blood differentiated adult tolerogenic dendritic cells expandedOther: Placebo
- Registration Number
- NCT04530318
- Lead Sponsor
- Judit Pich
- Brief Summary
The aim of this project is to assess properly the clinical efficacy of TolDec therapy by imaging, clinical and surrogate end-points related with the activity of the disease.
- Detailed Description
Our working hypothesis is to make a combination therapy with low-moderate efficacy immunomodulatory drugs with the aim of increasing efficacy without causing serious adverse effects such as those associated with the available high-efficacy therapies. Cellular therapies represent a highly specific treatment aimed to target selective "pathogenic" cells subsets. Tol-Dec loaded with immunogenic peptides interacts with Ag-specific T lymphocytes inducing regulatory T cells without affecting other cell subsets leading to a antinflammatory shift of immunological responses.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
- Age between 18-65 years old.
- Patients diagnosed with RRMS according to 2017 McDonald criteria.
- MS disease duration < 10 years.
- Expanded disability status scale (EDSS) from 0 to < 5.5.
- Patients eligible to start or already are in on treatment with first line immunomodulatory treatment (interferon beta 1a, interferon beta 1b, glatiramer acetate, teriflunomide or dymethyl-fumarate).
- Able to sign informed consent.
- Women of child-bearing potential must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence.
Exclusion Criteria
- Presence of a relapse or use of steroids 30 days prior to screening visit.
- Concomitant use of any type of immunomodulatory / immunosuppressive therapy.
- Use of previous immunosuppressive or cytotoxic therapy in the last 6 months. Use of previous alemtuzumab, cladribine or bone marrow or stem cell transplant at any time.
- Patients unable or unwilling to undergo MRI scans.
- Severe systemic diseases or history of cancer or hereditary familiar cancer.
- Clinically relevant concomitant disease: cardiac, gastrointestinal, hepatic, pulmonary, neurological, renal or other major disease.
- Impossibility to proceed to the leukapheresis (e.g. absence of peripheral venous access).
- Pregnant or breastfeeding women.
- Drug or alcohol abuse.
- Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS or to test positive for HIV antibody at screening.
- Ongoing known bacterial, viral or fungal infection (with the exception of onychomycosis and dermatomycosis), positive hepatitis B surface antigen or hepatitis C antibody tests at screening.
- Patients with a known history of syphilis or tuberculosis or test positive for syphilis (positive rapid plasma reagin, RPR) or tuberculosis (positive skin test) at screening. Active or latent tuberculosis (TB).
- Dementia or severe psychiatric, cognitive or behavioral problems or other comorbidity that may interfere with the compliance to the protocol.
- Any other clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the subject at risk by participating in the study.
- Participation in other experimental studies within the previous 90 days prior to screening visit.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description TolDec Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded Placebo Placebo Placebo of dendritic cells
- Primary Outcome Measures
Name Time Method Changes from baseline in the number of CUA lesion (mean number of the sum at week 12, 18 and 24). week 12, 18 and 24 Proportion of patients with any Grade 3 -4 adverse events related to product administration during the study period. week 24 Proportion of patients with any Grade 3 -4 adverse events related to study product. week 24
- Secondary Outcome Measures
Name Time Method Changes from baseline in the disability progression by Expanded Disability Status Scale (EDSS) at week 24. week 24 Time to first MS relapse during the study period. week 24 Proportion of patients with any Grade 3 -4 adverse events related to study product. week 24 Changes from baseline in the number of Gd-enhancing T1 lesions by scan (mean number of the sum at week 12, 18 and 24) and at week 24. week 24 Changes from baseline in MR measurements of diffuse damage of brain tissue by MTR at 24 weeks week 24 Changes from baseline in cytokine production (including IFNgamma, IL-17, IL-4 and IL-10) in response to specific peptide stimulation in peripheral blood mononuclear cells (PBMCs) culture supernatants at 12 and 24 weeks. week 24 Changes from baseline in the number of cortical lesions on MRI at 24 weeks. week 24 Changes from baseline in the disability progression by Multiple Sclerosis Functional Composite (MSFC) at week 24. week 24 Changes from baseline in the number of CUA lesion at week 24. week 24 Changes from baseline in brain global, white and gray matter volume and cervical cord volume on MRI at 24 weeks. week 24 Proportion of patients with any SAE events related to study product. week 24 Proportion of patients with at least one MS relapse during the study period. week 24 Total number of MS relapse at 24 weeks. week 24 Changes from baseline in number of new or enlarging T2 lesions by scan (mean number of the sum at week 12, 18 and 24) and at week 24. week 24 Changes in DTI measures as mean diffusivity (MD), fractional anisotropy (FA), radial diffusivity (Dr) and axial diffusivity (Da) at 24 weeks. week 24 Proportion of patients free from CUA lesion, gadolinium-enhancing lesions on T1 MRI and new or enlarged lesions on T2-MRI thought the 24 weeks of study. week 24 Changes from baseline in immune cell subsets in PBMCs including PBMC subtypes, T lymphocytes subpopulations and Treg subsets, CD4 and CD8 GM-CSF 'encephalitogenic' T cells and T cell subtypes by activation memory phenotype at 12 and 24 weeks. week 24 Changes from baseline in MR measurements of relaxation times of T1 and T2 by MTR at 24 weeks. week 24 Changes from baseline in T cell proliferation to immunogenic peptides at 12 and 24 weeks. week 24
Trial Locations
- Locations (5)
Hospital Universitari de Bellvitge
🇪🇸Hospitalet de Llobregat, Barcelona, Spain
Hospital Moisés Broggi
🇪🇸Hospitalet de Llobregat, Barcelona, Spain
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital ClÃnic de Barcelona
🇪🇸Barcelona, Spain
Hospital de Sant Pau
🇪🇸Barcelona, Spain